Bristol Myers Squibb sues Biden administration over Medicare drug negotiations in third such lawsuit
- Bristol Myers Squibb has sued the Biden administration over Medicare's new powers to negotiate drug prices under the Inflation Reduction Act.
- The drugmaker said its blood thinner Eliquis will be subject to the negotiations later this year.
- Bristol Myer Squibb's complaint mirrors the arguments made last week by Merck, the first company to sue over the law.
- The U.S. Chamber of Commerce also sued the Biden administration last week.
Bristol Myers Squibb on Friday sued the Biden administration over Medicare's new powers to slash drug prices, the third such lawsuit to be filed against the program in a matter of days.
The lawsuit filed in federal district court in New Jersey argues the Medicare negotiations violate the First and Fifth Amendments of the U.S. Constitution.
Bristol Myers Squibb has asked the court to declare the program unconstitutional and prevent the Health and Human Services Department from forcing the company to enter negotiations.
Bristol Myers Squibb's arguments mirror those lodged last week by Merck, the first company to sue the federal government over the drug negotiations. The U.S. Chamber of Commerce has also sued HHS over the program with similar arguments.
The Inflation Reduction Act, passed in 2022 in a narrow party-line vote, empowered Medicare to negotiate drug prices for the first time in the program's six-decade history. The law is the central pillar in the Biden administration's efforts to control rising drug prices and was a major victory for the Democratic Party.
Bristol Myers Squibb said its blood thinner Eliquis, used to treat clots and strokes, will be subject to the negotiations this year. The company generated $11.8 billion in revenue from Eliquis last year, about 25% of the company's $46 billion in total revenue for 2022.
The drugmaker also said Opdivo, used to treat several types of cancer, will be subject to the Medicare negotiations in the future. Opdivo generated $8.2 billion in sales for the company in 2022, which made up about 18% of the drugmaker's total revenue for that year.
Bristol Myers Squibb argued the federal government is forcing the company to enter negotiations and eventually agree to a heavily discounted price. The company claims this violates Fifth Amendment protections against the government seizing private property without just compensation.
The drugmaker also claimed HHS is forcing the company to publicly present the program as a negotiation over a fair price. The company called the negotiations a sham and claimed the federal government is forcing the drugmaker to "parrot its preferred political messaging" in violation of the First Amendment.
HHS Secretary Xavier Becerra, in a statement after Merck's lawsuit last week, vowed to vigorously defend the Inflation Reduction Act in court, saying, "The law is on our side."
White House Press Secretary Karine Jean-Pierre, also in a statement after Merck's suit, said the Biden administration is confident it will win in court.
"There is nothing in the Constitution that prevents Medicare from negotiating lower drug prices," Jean-Pierre said.